Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on June 16, 2025. The report discloses a corporate governance event regarding the appointment of a new executive officer and the modification of his compensatory arrangements, effective June 16, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation changes and does not contain financial performance data.
Material Changes
The primary material change disclosed is the promotion and compensation adjustment for Frank Mottola:
- Role Change: Appointed as Chief Technical Operations Officer, effective June 16, 2025 (previously Senior Vice President, Quality, GMP Operations and IT).
- Base Salary Increase: Increased from $392,500 to $412,500 annually.
- Bonus Target Increase: Increased from 35% to 40% of base salary for the 2025 fiscal year.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the disclosure of the executive appointment and compensation terms.
Investor Verification Checklist
- Verify the effective date of Frank Mottola's new title and compensation terms (June 16, 2025).
- Confirm the specific dollar amounts of the base salary increase ($20,000) and the percentage increase in the bonus target (5% points).
- Review the Company's most recent 10-Q or 10-K for financial performance data, as this 8-K does not contain such metrics.